Scaricare la presentazione
La presentazione è in caricamento. Aspetta per favore
PubblicatoOsborn Rodgers Modificato 6 anni fa
1
An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia by Marco Montillo, Alessandra Tedeschi, Valeria Belsito Petrizzi, Francesca Ricci, Monica Crugnola, Mauro Spriano, Pierangelo Spedini, Fiorella Ilariucci, Lilj Uziel, Immacolata Attolico, Eleonora Vismara, Angelo De Blasio, Alfonso Zaccaria, and Enrica Morra Blood Volume 118(15): October 13, 2011 ©2011 by American Society of Hematology
2
PFS and OS of patients receiving FCC. (A) PFS in responders.
PFS and OS of patients receiving FCC. (A) PFS in responders. (B) PFS according to response (CR vs PR). (C) OS in all 43 enrolled patients. (D) OS in responders. Marco Montillo et al. Blood 2011;118: ©2011 by American Society of Hematology
Presentazioni simili
© 2024 SlidePlayer.it Inc.
All rights reserved.